Trial Profile
A retrospective study of daratumumab in combination with pomalidonide and dexamethasone in multiple myeloma patients who are naive to treatment with or refractory to daratumumab alone, pomalidomide alone or to the combination of daratumumab and pomalidomide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 15 May 2019 Results (n=34) published in the Cancer
- 24 Jan 2017 New trial record